Septerna (NASDAQ:SEPN) Rating Lowered to “Equal Weight” at Wells Fargo & Company

Septerna (NASDAQ:SEPN) was downgraded by Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a report issued on Tuesday,Briefing.com Automated Import reports. They currently have a $14.00 target price on the stock. Wells Fargo & Company‘s price target points to a potential upside of 8.02% from the company’s current price.

Other equities research analysts also recently issued reports about the company. JPMorgan Chase & Co. started coverage on Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $38.00 price target for the company. Cantor Fitzgerald restated an “overweight” rating and set a $50.00 price target on shares of Septerna in a research note on Tuesday, February 11th. Finally, TD Cowen started coverage on Septerna in a research note on Tuesday, November 19th. They set a “buy” rating for the company.

Septerna Stock Up 12.2 %

Septerna stock opened at $12.96 on Tuesday. The company’s 50-day moving average price is $19.15. Septerna has a 52-week low of $10.34 and a 52-week high of $28.99.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. bought a new position in shares of Septerna during the 4th quarter valued at approximately $160,205,000. TRV GP V LLC bought a new position in shares of Septerna during the 4th quarter valued at approximately $142,337,000. TRV GP VI LLC bought a new position in shares of Septerna during the 4th quarter valued at approximately $72,191,000. Samsara BioCapital LLC bought a new position in shares of Septerna during the 4th quarter valued at approximately $63,399,000. Finally, Driehaus Capital Management LLC bought a new position in shares of Septerna during the 4th quarter valued at approximately $59,301,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.